{"id":5646,"date":"2020-03-17T07:00:00","date_gmt":"2020-03-17T06:00:00","guid":{"rendered":"https:\/\/staybletherapeutics.com\/sv\/cision-feed\/stayble-har-skickat-in-ansokningar-till-regulatoriska-myndigheter-i-spanien-om-start-av-klinisk-fas-2b-studie\/"},"modified":"2020-03-17T07:00:00","modified_gmt":"2020-03-17T06:00:00","slug":"stayble-har-skickat-in-ansokningar-till-regulatoriska-myndigheter-i-spanien-om-start-av-klinisk-fas-2b-studie","status":"publish","type":"cision-feed","link":"https:\/\/staybletherapeutics.com\/sv\/cision-feed\/stayble-har-skickat-in-ansokningar-till-regulatoriska-myndigheter-i-spanien-om-start-av-klinisk-fas-2b-studie\/","title":{"rendered":"Stayble har skickat in ans\u00f6kningar till regulatoriska myndigheter i Spanien om start av klinisk fas 2b studie."},"content":{"rendered":"<p><span style=\"font-size:10pt\"><span style=\"line-height:115%\"><span style=\"color:#3b3838\"><span style=\"font-family:tahoma,arial,helvetica,sans-serif\">VD Andreas Gerward kommenterar: Att vi skickat in ans\u00f6kan till samtliga regulatoriska myndigheter \u00e4r ett viktigt steg mot start av studien och en viktig milstolpe f\u00f6r bolaget. Vi ser nu fram emot att kunna inleda studien under Q2 2020. <\/span><\/span><\/span><\/span><\/p>\n<p><span style=\"font-size:10pt\"><span style=\"line-height:115%\"><span style=\"color:#3b3838\"><span style=\"font-family:tahoma,arial,helvetica,sans-serif\">M\u00e5let med den klinisk fas 2b pr\u00f6vningen \u00e4r att p\u00e5visa en s\u00e4kerhet och tolerabilitet och klinisk relevant minskning i sm\u00e4rta i patienter. Studien kommer att inkludera ca 100 patienter och genomf\u00f6ras vid ca 20 kliniker i Nederl\u00e4nderna, Ryssland och Spanien. <\/span><\/span><\/span><\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Bolaget kan meddela att ytterligare ett viktigt steg f\u00f6r start av klinisk fas 2b studie med STA363 under Q2 har genomf\u00f6rts. Bolaget har nu ocks\u00e5 skickat in ans\u00f6kningar till regulatoriska myndigheter i Spanien samt tidigare i Ryssland och Nederl\u00e4nderna. Bolaget har d\u00e4rmed skickat in samtliga ans\u00f6kningar till regulatoriska myndigheter i de tre l\u00e4nderna som Bolagets fas 2b-studie planeras att genomf\u00f6ras i.<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"_links":{"self":[{"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/cision-feed\/5646"}],"collection":[{"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/cision-feed"}],"about":[{"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/types\/cision-feed"}],"replies":[{"embeddable":true,"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/comments?post=5646"}],"version-history":[{"count":0,"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/cision-feed\/5646\/revisions"}],"wp:attachment":[{"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/media?parent=5646"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}